Injection of a modified virus for advanced GI and peritoneal cancers
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 69 years old.
- Your cancer must have spread from your gastrointestinal tract or the lining of your belly (peritoneum).
- You must have tried at least two standard chemotherapies or, if your tumor is MSI-high, you must have tried immunotherapy as well.
- You need to be in fairly good health (able to perform daily activities) and have a life expectancy of at least 12 weeks.
- You must have at least one tumor that is safely reachable with a needle for injection.
- You cannot have used steroids or other immune-suppressing medicines within 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
This trial tests combining a special virus injected directly into the tumor with two approved drugs (tislelizumab and lenvatinib) for advanced liver cancer that hasn't been treated before. The goal is to see if this triple approach can shrink tumors and improve outcomes.
This study tests whether a special virus injected directly into tumors can help your body fight cancer when combined with an immunotherapy drug. It is for people with advanced colorectal, stomach, or liver cancer that has spread and who have tumors that can be reached for injection.
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.